High-risk human papillomavirus genotype distribution among women living with HIV; implication for cervical cancer prevention in a resource limited setting

Infectious Agents and Cancer
Patrick Kafui Akakpo1, Sebastian Ken‐Amoah2, Nancy Innocentia Ebu Enyan3, Elizabeth Agyare4, Emmanuel Salia5, Ibrahim Baidoo4, Leonard Derkyi-Kwarteng1, Matthew Asare6, George Adjei7, Stephen Ayisi Addo8, Dorcas Obiri‐Yeboah5
1Department of Anatomic Pathology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana
2Department of Obstetrics and Gynaecology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana
3Department of Adult Health, School of Nursing and Midwifery, University of Cape Coast, Cape Coast, Ghana
4Public Health Unit, Cape Coast Teaching Hospital, Cape Coast, Ghana
5Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana
6Department of Public Health, Robbins College of Health and Human Services, Baylor University, Waco, TX, USA
7Department of Community Medicine, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana
8National AIDS/STIs Control Programme, Korle-Bu, Accra, Ghana

Tóm tắt

Abstract Background For women living with HIV (WLHIV), the burden of persistent HPV infection, cervical pre-cancerous lesions and cancer have been demonstrated to be higher than among HIV-negative women. As Ghana and other lower-middle-income countries (LMIC) work toward developing national cervical cancer programmes, it is essential that local scientific evidence be provided to guide policy decisions, especially for such special populations. The objective of this study was to determine the distribution of high-risk HPV genotype and related factors among WLHIV and its implication for the prevention of cervical cancer prevention efforts. Methods A cross-sectional study was conducted at the Cape Coast Teaching Hospital in Ghana. WLHIV, aged 25–65 years, who met the eligibility criteria were recruited through a simple random sampling method. An interviewer-administered questionnaire was used to gather socio-demographic, behavioural, clinical and other pertinent information. The AmpFire HPV detection system (Atila BioSystem, Mointain View, CA was used to detect 15 high-risk HPV genotypes from self-collected cervico-vaginal samples. The data collected were exported to STATA 16.0 for statistical analysis. Results In all, 330 study participants, with mean age of 47.2 years (SD ± 10.7), were involved. Most (69.1%, n = 188/272) had HIV viral loads < 1000 copies/ml and 41.2% (n = 136) had ever heard of cervical screening. The overall hr-HPV prevalence was 42.7% (n = 141, 95% CI 37.4–48.1) and the five commonest hr-HPV types among screen positives were HPV59 (50.4%), HPV18 (30.5%), HPV35 (26.2%), HPV58 (17%) and HPV45 (14.9%). Most infected women (60.3%, n = 85) had multiple hr-HPV infections, with about 57.4% (n = 81) having 2–5 h-HPV types, while 2.8% (n = 4) had more than five hr-HPV types. A total of 37.6% (n = 53) had HPV16 and/or18, while 66.0% (n = 93) had the hr-HPV genotypes covered by the nonavalent vaccine. Women with HIV viral load ≥ 1000copies/ml (AOR = 5.58, 95% CI 2.89–10.78, p < 0.001) had a higher likelihood of being co-infected. Conclusion This study found out that the prevalence of hr-HPV still remains high in women with HIV, with a notable occurrence of multiple infections and infection with genotypes 16 and/or18. Additionally, an association was established between hr-HPV and infection HIV viral load.. Therefore, comprehensive HIV care for these women should include awareness of cervical cancer, consideration of vaccination and implementation of screening and follow-up protocols. National programmes in LMIC, such as Ghana, should consider using HPV-based screen-triage-treat approach with partial genotyping.

Từ khóa


Tài liệu tham khảo

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries - PubMed [Internet]. [cited 2022 Mar 22].

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-203.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–89.

Alhamlan FS, Al-Zahrani AS, Almatrrouk SA, Al-Ahdal MN. Human papillomaviruses: the cervical cancer saga in developing countries. J Infect Dev Ctries. 2017;11(11):819–25.

Jedy-Agba E, Joko WY, Liu B, Gyabi Buziba N, Borok M, Korir A, et al. Epidemiology trends in cervical cancer incidence in sub-Saharan Africa. Br J Cancer. 2020;123(1):148–54.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Human Papillomavirus and Related Diseases Report WORLD.

Traore IM, Zohoncon TM, Dembele A, Djigma FW, Obiri-Yeboah D, Traore G, Bambara M, Ouedraogo C, Traore Y, Simpore J. Molecular Characterization of High-Risk Human Papillomavirus in Women in Bobo-Dioulasso, Burkina Faso. Biomed Res Int. 2016;2016:7092583. https://doi.org/10.1155/2016/7092583.

Didelot-Rousseau MN, Nagot N, Costes-Martineau V, Vallès X, Ouedraogo A, Konate I, et al. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer. 2006;95(3):355–62.

IARC Publications Website—Human Papillomaviruses [Internet]. [cited 2023 Apr 26]. https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Human-Papillomaviruses-2007

HPV and Cancer - National Cancer Institute [Internet]. [cited 2022 Mar 29]. https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer

Obiri-Yeboah D, Akakpo PK, Mutocheluh M, Adjei-Danso E, Allornuvor G, Amoako-Sakyi D, Adu-Sarkodie Y, Mayaud P. Epidemiology of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL) among a cohort of HIV-infected and uninfected Ghanaian women. BMC Cancer. 2017;17(1):688.

Awua AK, Sackey ST, Osei YD, Asmah RH, Wiredu EK. Prevalence of human papillomavirus genotypes among women with cervical cancer in Ghana. Infect Agent Cancer. 2016;11:4. https://doi.org/10.1186/s13027-016-0050-4.

Behnke AL, Höfler D, Pawlita M, Kaufmann AM. Characterization of Human Papillomavirus prevalence and risk factors to guide cervical cancer screening in the North Tongu District, Ghana. PLoS One. 2019;14(6):e0218762. https://doi.org/10.1371/journal.pone.0218762.

Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection on JSTOR [Internet]. [cited 2022 Mar 29]. https://www.jstor.org/stable/48504311

Denny LA, Franceschi S, de Sanjosé S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 2012;30(Suppl 5):F168–74. https://doi.org/10.1016/j.vaccine.2012.06.045.

Grinsztejn B, Veloso VG, Levi JE, Velasque L, Luz PM, Friedman RK, et al. Factors associated with increased prevalence of human papillomavirus infection in a cohort of HIV-infected Brazilian women. Int J Infect Dis. 2009;13(1):72–80.

Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P, Qiao YL, et al. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(1):e45-58.

Konopnicki D, Manigart Y, Gilles C, Barlow P, De Marchin J, Feoli F, et al. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women. J Infect Dis. 2013;207(11):1723–9.

Blitz S, Baxter J, Raboud J, Walmsley S, Rachlis A, Smaill F, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in hiv-positive and high-risk HIV-negative women. J Infect Dis. 2013;208(3):454–62.

Zur HH. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50.

Li J, Mei J, Wang X, Hu L, Lin Y, Yang P. Human papillomavirus type-specific prevalence in women with cervical intraepithelial neoplasm in Western China. J Clin Microbiol. 2012;50(3):1079–81.

Louie KS, De Sanjose S, Mayaud P. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: A comprehensive review. Tropical Med Int Health. 2009;14(10):1287–302.

Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17.

Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJF, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366(9490):991–8.

Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907.

Ebu NI, Mupepi SC, Siakwa MP, Sampselle CM. Knowledge, practice, and barriers toward cervical cancer screening in Elmina, Southern Ghana. Int J Womens Health. 2014;24(7):31–9.

Drokow EK, Zi L, Han Q, Effah CY, Agboyibor C, Sasu E, et al. Awareness of cervical cancer and attitude toward human papillomavirus and its vaccine among Ghanaians. Front Oncol. 2020;8:10.

Williams MS, Kenu E, Adanu A, Yalley RA, Lawoe NK, Dotse AS, et al. Awareness and beliefs about cervical cancer, the HPV vaccine, and cervical cancer screening among Ghanaian women with diverse education levels. J Cancer Educ. 2019;34(5):897–903.

Ebu NI, Mupepi SC, Siakwa MP, Sampselle CM. Knowledge, practice, and barriers toward cervical cancer screening in Elmina. Southern Ghana Int J Womens Health. 2014;24(7):31–9.

Stuart A, Obiri-Yeboah D, Adu-Sarkodie Y, Hayfron-Benjamin A, Akorsu AD, Mayaud P. Knowledge and experience of a cohort of HIV-positive and HIV-negative Ghanaian women after undergoing human papillomavirus and cervical cancer screening. BMC Womens Health. 2019;19(1):1–11.

Fitzpatrick M, Pathipati MP, McCarty K, Rosenthal A, Katzenstein D, Chirenje ZM, et al. Knowledge, attitudes, and practices of cervical cancer screening among HIV-positive and HIV-negative women participating in human papillomavirus screening in rural Zimbabwe. BMC Womens Health. 2020;20(1):1–10.

Luque AE, Hitti J, Mwachari C, Lane C, Messing S, Cohn SE, Adler D, Rose R, Coombs R. Prevalence of human papillomavirus genotypes in HIV-1-infected women in Seattle, USA and Nairobi, Kenya: results from the Women's HIV Interdisciplinary Network (WHIN). Int J Infect Dis. 2010;14(9):e810–4. https://doi.org/10.1016/j.ijid.2010.03.016.

Acheampong LK, Effah K, Amuah JE, Tekpor E, Wormenor CM, Gedzah I, Kemawor S, Kachana AC, Danso PA, Essel NOM, Asomaning M, Agyiri D, Akakpo PK. Determining the prevalence of high-risk human papillomavirus infection using a novel cervical precancer screening approach in incarcerated women at the Nsawam Medium Security Prison, Ghana. Ecancermedicalscience. 2021;15:1248. https://doi.org/10.3332/ecancer.2021.1248.

Devine A, Vahanian A, Sawadogo B, Zan S, Bocoum FY, Kelly H, Gilham C, Nagot N, Ong JJ, Legood R, Meda N, Miners A, Mayaud P. HARP Consortium. Costs and cost-effectiveness of cervical cancer screening strategies in women living with HIV in Burkina Faso: The HPV in Africa Research Partnership (HARP) study. PLoS One. 2021;16(3):e0248832. https://doi.org/10.1371/journal.pone.0248832.

Shiferaw S, Addissie A, Gizaw M, Hirpa S, Ayele W, Getachew S, Kantelhardt EJ, Assefa M, Jemal A. Knowledge about cervical cancer and barriers toward cervical cancer screening among HIV-positive women attending public health centers in Addis Ababa city, Ethiopia. Cancer Med. 2018;7(3):903–12.

Enyan NIE, Davies AE, Opoku-Danso R, Annor F, Obiri-Yeboah D. Correlates of cervical cancer screening participation, intention and self-efficacy among Muslim women in southern Ghana. BMC Womens Health. 2022;22(1):114.

Ermel A, Tonui P, Titus M, Tong Y, Wong N, Ong’echa J, et al. A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women. BMC Infect Dis. 2019;19(1):1–8.

Munk AC, Gudlaugsson E, Malpica A, Fiane B, Løvslett KI, Kruse AJ, Øvestad IT, Voorhorst F, Janssen EA, Baak JP. Consistent condom use increases the regression rate of cervical intraepithelial neoplasia 2–3. PLoS One. 2012;7(9):e45114. https://doi.org/10.1371/journal.pone.0045114.

Xu H, Egger S, Velentzis LS, OConnell DL, Banks E, Darlington-Brown J, et al. Hormonal contraceptive use and smoking as risk factors for high-grade cervical intraepithelial neoplasia in unvaccinated women aged 30–44 years: a case-control study in New South Wales. Australia Cancer Epidemiol. 2018;55:162–9.

Menon S, Rossi R, Zdraveska N, Kariisa M, Acharya SD, Vanden Broeck D, et al. Associations between highly active antiretroviral therapy and the presence of HPV, premalignant and malignant cervical lesions in sub-Saharan Africa, a systematic review: Current evidence and directions for future research. BMJ Open. 2017;7(8):e015123.

Bogale AL, Teklehaymanot T, Ali JH, Kassie GM. Knowledge, attitude and practice of cervical cancer screening among women infected with HIV in Africa: systematic review and metaanalysis. PLoS ONE. 2021;16(4):e0249960.

Yar DD, Salifu SP, Darko SN, Annan AA, Gyimah AA, Buabeng KO, et al. Genotypic characterisation of human papillomavirus infections among persons living with HIV infection: a case–control study in Kumasi, Ghana. Trop Med Int Health. 2016;21(2):275–82.

Mbatha JN, Taylor M, Kleppa E, Lillebo K, Galapaththi-Arachchige HN, Singh D, et al. Infectious diseases high-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination High-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination. Infect Dis. 2017;49(8):601–8.

Zhang W, Du H, Huang X, Wang C, Duan X, Liu Y, Shi B, Zhang W, Qu X, Wei L, Schiffman M, Belinson JL, Wu R. Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening. Infect Agent Cancer. 2020;15:65. https://doi.org/10.1186/s13027-020-00328-1.

Castle PE, Einstein MH, Sahasrabuddhe VV. Cervical cancer prevention and control in women living with human immunodeficiency virus. CA Cancer J Clin. 2021;71(6):505–26.

WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Ebu NI. Facilitators and barriers to cervical cancer screening among HIV-positive women in Ghana. Afr J Midwifery and Women’s Health. 2018;12(2):93–9.

Mukuku O, Womens A. Barriers and facilitators to cervical cancer prevention in Mbuji-Mayi Democratic Republic of Congo: a qualitative study. Annals of Women's Health. 2020;4(1):1017.

Yong CJ, Hong LL, Lee KY, Krishnasamy I, Nasir NHB, Gravitt P, et al. Healthcare providers’ views on cervical screening: a qualitative study of barriers to cervical screening in Malaysia. Amer Soc Clin Oncol J. 2018;4(Supplement 2):214s. https://doi.org/10.1200/jgo.18.86300.

Dunyo P, Effah K, Udofia EA. Correction to: Factors associated with late presentation of cervical cancer cases at a district hospital: a retrospective study. BMC Public Health. 2018;18:1243. https://doi.org/10.1186/s12889-018-6127-9.

Mensah K, Assoumou N, Duchesne V, Pourette D, DeBeaudrap P, Dumont A. Acceptability of HPV screening among HIV-infected women attending an HIV-dedicated clinic in Abidjan, Côte d’Ivoire. BMC Womens Health. 2020;20(1):155. https://doi.org/10.1186/s12905-020-01021-6.

Belglaiaa E, Elannaz H, Mouaouya B, Aksim M, Mercier M, Prétet JL, et al. Human papillomavirus genotypes among women with or without HIV infection: an epidemiological study of Moroccan women from the Souss area. Infect Agent Cancer. 2015;10(1):10.

Ebu NI, Ogah JK. Predictors of cervical cancer screening intention of HIV-positive women in the central region of Ghana. BMC Women's Health. 2018;18(1):1–7.

Adedimeji A, Ajeh R, Pierz A, Nkeng R, Ndenkeh JJ, Fuhngwa N, et al. Challenges and opportunities associated with cervical cancer screening programs in a low income, high HIV prevalence context. BMC Womens Health. 2021;21(1):1–14.

Ebu NI, Amissah-Essel S, Asiedu C, Akaba S, Pereko KA. Impact of health education intervention on knowledge and perception of cervical cancer and screening for women in Ghana. BMC Public Health. 2019;19(1):1–11.

Ebu NI. Socio-demographic characteristics influencing cervical cancer screening intention of HIV-positive women in the central region of Ghana. Gynecol Oncol Res Pract. 2018;5:3. https://doi.org/10.1186/s40661-018-0060-6.

Roik E, Sharashova E, Kharkova O, Nieboer E, Postoev V, Odland JØ. Sociodemographic characteristics, sexual behaviour and knowledge about cervical cancer prevention as risk factors for high-risk human papillomavirus infection in Arkhangelsk, North-West Russia. Int J Circumpolar Health. 2018;77(1):1498681

Zidi S, Sahli M, Mezlini A, Yacoubli-Loueslati B. Association of combined tobacco smoking, hormonal contraceptive use and status matrimonial with cervical cancer evolution in Tunisian Women. Pathol Oncol Res. 2018;26(1):217–22.

Arfailasufandi R, Mudigdo A, Sudiyanto A. The effect of obesity, oral contraceptive and passive smoking on the risk of cervical cancer. J Epidemiol Public Health. 2019;4(3):189–97.

Bogale AL, Belay NB, Medhin G, Ali JH. Molecular epidemiology of human papillomavirus among HIV infected women in developing countries: systematic review and meta-analysis. Virol J. 2020;17(1):1–15.

Castle PE, Ajeh R, Dzudie A, Kendowo E, Fuhngwa N, Simo-Wambo AG, et al. A comparison of screening tests for detection of high-grade cervical abnormalities in women living with HIV from Cameroon. Infect Agent Cancer. 2020;15(1):45.

Kelly HA, Chikandiwa A, Sawadogo B, Gilham C, Michelow P, Lompo OG, et al. Diagnostic accuracy of cervical cancer screening and screening–triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study. PLoS Med. 2021;18(3):e1003528.

Obiri-Yeboah D, Adu-Sarkodie Y, Djigma F, Akakpo K, Aniakwa-Bonsu E, Amoako-Sakyi D, et al. Erratum to: Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana. Gynecol Oncol Res Pract. 2017;4(1):8.

Duan R, Zhao X, Zhang H, Xu X, Huang L, Wu A, et al. Performance of cervical cancer screening and triage strategies among women living with HIV in China. Cancer Med. 2021;10(17):6078–88.

Desai KT, Ajenifuja KO, Banjo A, Adepiti CA, Novetsky A, Sebag C, et al. Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. Infect Agent Cancer. 2020;15(1):1–13.

(PDF) Molecular Genotyping of Human Papillomavirus among HIV-infected and HIV-uninfected Women in Ouagadougou, Burkina Faso [Internet]. [cited 2022 Jul 23]. https://www.researchgate.net/publication/339021039_Molecular_Genotyping_of_Human_Papillomavirus_among_HIV-infected_and_HIV-uninfected_Women_in_Ouagadougou_Burkina_Faso

Debrah O, Agyemang-Yeboah F, Donkoh ET, et al. Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study. BMC Women’s Health. 2021;21:372.

Mbulawa ZZA, Phohlo K, Garcia-Jardon M, Williamson AL, Businge CB. High human papillomavirus (HPV)-35 prevalence among South African women with cervical intraepithelial neoplasia warrants attention. PLoS ONE. 2022;17(3):e0264498.

Id ZN, Vanden BD, Lisbeth R, Id L, Bogers J, Benoy I, et al. Prevalence and genotype-specific distribution of human papillomavirus in Burundi according to HIV status and urban or rural residence and its implications for control. PLoS ONE. 2019;14(6):e0209303.

Baussano I, Sayinzoga F, Tshomo U, Tenet V, Vorsters A, Heideman DAM, Gheit T, Tommasino M, Umulisa MC, Franceschi S, Clifford GM. Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan. Emerg Infect Dis. 2021;27(1):1–9. https://doi.org/10.3201/eid2701.191364.

Campos NG, Kim JJ, Castle PE, Ortendahl JD, O’Shea M, Diaz M, et al. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer. 2012;130(11):2672.

Okoye JO, Ofodile CA, Adeleke OK, Obioma O. Prevalence of high-risk HPV genotypes in sub-Saharan Africa according to HIV status: a 20-year systematic review. Epidemiol Health. 2021;43.

Seek AC, Faye MA, Mbaye AD, De EB, Kuypers J, Kiviat NB, et al. Cervical intraepithelial neoplasia and human papillomavirus infection among senegalese women seropositive for HIV-1 or HIV-2 or seronegative for HIV. Int J STD Aids. 1994;5(3):189–93.

Thông tin
Thông tin xuất bản

Infectious Agents and Cancer

Thông tin tác giả